Bisphosphonate-Related Osteonecrosis of the Jaw Combined With Jaw Metastasis of Prostate Adenocarcinoma: Report of a Case

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 4, 2010, Pages 863-867

  Frei, Marc ^a   Bornstein, Michael M ^a   Schaller, Benoit ^b   Reichart, Peter A ^a   Weimann, Rosemarie ^a   Iizuka, Tateyuki ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; BISPHOSPHONIC ACID DERIVATIVE; CLAVULANIC ACID; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; DEBRIDEMENT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JAW; JAW OSTEONECROSIS; MALE; PERIODONTAL LIGAMENT; PROSTATE ADENOCARCINOMA; WOUND;

ADENOCARCINOMA; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MANDIBULAR DISEASES; MANDIBULAR NEOPLASMS; MIDDLE AGED; OSTEONECROSIS; PROSTATIC NEOPLASMS;

EID: 77949456025     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.11.015     Document Type: Article

References (28)

1. Fleisch H., Russell R., and Francis M. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165 (1969) 1262
2. Rogers M.J., Watts D.J., and Russell R.G. Overview of bisphosphonates. Cancer 80 (1997) 1652
3. Rodan G.A., and Fleisch H.A. Bisphosphonates: Mechanisms of action. J Clin Invest 97 (1996) 2692
4. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538
5. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055
6. Migliorati C. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 (2003) 4253
7. Hubner R.A., and Houston S.J. Bisphosphonates' use in metastatic bone disease. Hosp Med 66 (2005) 414
8. Landesberg R., Eisig S., Fennoy I., et al. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg 67 (2009) 27
9. Ruggiero S.L., Dodson T.B., Assael L.A., et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 Update. J Oral Maxillofac Surg 67 (2009) 2
10. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
11. Marx R.E. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment (2007), Quintessence Publishing, Hanover Park, IL 77
12. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479
13. Rodan G.A. The development and function of the skeleton and bone metastases. Cancer 97 (2003) 726
14. D'Silva N.J., Summerlin D.J., Cordell K.G., et al. Metastatic tumors in the jaws: A retrospective study of 114 cases. J Am Dent Assoc 137 (2006) 1667
15. Body J.J. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 12 (2003) 37
16. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580
17. Hirshberg A., Shnaiderman-Shapiro A., Kaplan I., et al. Metastatic tumours to the oral cavity-Pathogenesis and analysis of 673 cases. Oral Oncol 44 (2008) 743
18. Hirshberg A., Leibovich P., Horowitz I., et al. Metastatic tumours to postextraction sites. J Oral Maxillofac Surg 51 (1993) 1334
19. Boonyapakorn T., Schirmer I., Reichart P.A., et al. Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 (2008) 857
20. Walter C., Al-Nawas B., Grötz K.A., et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54 (2008) 1066
21. Cartsos V.M., Zhu S., and Zavras A.I. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc 139 (2008) 23
22. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24 (2006) 94
23. Ruggiero S.L., and Woo S.B. Biophosphonate-related osteonecrosis of the jaws. Dent Clin North Am 52 (2008) 111
24. Arce K., Assael L.A., Weissman J.L., et al. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 67 (2009) 75
25. Hansen T., Kunkel M., Springer E., et al. Actinomycosis of the jaws-Histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451 (2007) 1009
26. Fantasia J.E. Bisphosphonates-What the dentist needs to know: Practical considerations. J Oral Maxillofac Surg 67 (2009) 53
27. Lazarovici T.S., Yahalom R., Taicher S., et al. Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients. J Oral Maxillofac Surg 67 (2009) 850
28. Almazrooa S.A., and Woo S.B. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: A review. J Am Dent Assoc 140 (2009) 864